Advertisement
Screener

Vivos Therapeutics, Inc. (VVOS) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

1.4 / 5 stars · 15/52 Roast Me

Vivos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

Vivos Therapeutics, Inc. (VVOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 112.00% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2023-03-30

  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 135.00%, a 0.75% increase year-over-year.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 134.00%, a 0.00% change year-over-year.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-03-31 was 134.00%.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 112.00%, a 20.57% decline from fiscal 2021.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 141.00%, a 5.22% increase from fiscal 2020.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 134.00%, a 9.84% increase from fiscal 2019.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2019 was 122.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2022-12-31112.00%
10-K · filed 2023-03-30
2022-09-30135.00%
10-Q · filed 2022-12-20
2022-06-30135.00%
10-Q · filed 2022-12-20
2022-03-31135.00%
10-Q/A · filed 2022-11-25
2021-12-31141.00%
10-K · filed 2023-03-30
2021-09-30141.00%
10-Q · filed 2022-12-20
2021-06-30137.00%
10-Q · filed 2021-08-12
2021-03-31134.00%
10-Q · filed 2021-05-17
2020-12-31134.00%
10-K · filed 2022-03-31
2020-03-31134.00%
10-Q · filed 2021-05-17
2019-12-31122.00%
10-K · filed 2021-03-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
NEXGEL, INC. (NXGL)United States$0.002B
INVO Fertility, Inc. (IVF)United States$0.002B-0.71
Catheter Precision, Inc. (VTAK)United States$0.002B-0.23
Tenon Medical, Inc. (TNON)United States$0.002B
Autonomix Medical, Inc. (AMIX)United States$0.004B
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Profusa, Inc. (PFSA)United States$0.002B
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Bluejay Diagnostics, Inc. (BJDX)United States$0.004B